Journal of Affective Disorders
Volume 86, Issue 1 , Pages 37-45 , May 2005

Dopaminergic mechanism of antidepressant action in depressed patients

  • Paul Willner

      Affiliations

    • Department of Psychology, University of Wales Swansea, Swansea SA2 8PP, UK
    • Corresponding Author InformationCorresponding author. Tel.: +1 792 295844; fax: +1 792 295679.
    • ,
  • Anthony S. Hale

      Affiliations

    • Kent Institute of Medicine and Health Sciences, University of Kent at Canterbury, Canterbury CT2 7NZ, UK
    • ,
  • Spilios Argyropoulos

      Affiliations

    • Psychopharmacology Unit, University of Bristol, Bristol BS8 1TD, UK

Received 5 September 2004 ,Revised 6 December 2004 ,Accepted 8 December 2004.

References 

  1. Bond AJ, Lader M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 1974;47:211–218
  2. Bowden C, Theodorou AE, Cheetham SC, Lowther S, Katona CL, Crompton MR, et al. Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls. Brain Res. 1997;752:227–233
  3. Caley CF. Extrapyramidal reactions from concurrent SSRI and atypical antipsychotic use. Can. J. Psychiatry. 1998;43:307–308
  4. D'Aquila P, Monleon S, Borsini F, Brain P, Willner P. Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant. Eur. J. Pharmacol. 1997;340:121–132
  5. Del Zompo M, Bocchetta A, Bernardi F, Burrai C, Corsini GU. Clinical evidence for a role of dopaminergic system in depressive syndromes. In:  Gessa GL,  Serra G editor. Dopamine and mental depression. Oxford: Pergamon; 1990;p. 177–184
  6. D'haenen H, Bossuyt A. Dopamine D2 receptors in the brain measured with SPECT. Biol. Psychiatry. 1994;15:128–132
  7. D'haenen H, Steensens D, Bossuyt A. Successful antidepressant treatment with SSRIs is associated with an increased D2 binding. Int. J. Neuropsychopharmacol. 1999;2:S14
  8. Drago F, Arezzi A, Virzi A. Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats. Eur. Neuropsychopharmacol. 2000;10:437–442
  9. Ebert D, Feistel H, Loew T, Priner A. Dopamine and depression: striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology. 1996;126:91–94
  10. Fawcett J, Clark DC, Scheftner WA, Gibbons RD. Assessing anhedonia in psychiatric patients: the pleasure scale. Arch. Gen. Psychiatry. 1983;40:79–84
  11. Klimke A, Larisch R, Janz A, Vosberg H, Muller-Gartner HW, Gaebel W. Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry Res. 1999;26:91–101
  12. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J. Psychopharmacol. 1998;12:192–214
  13. Larisch R, Klimke A, Vosberg H, Loffler S, Gaebel W, Muller-Gartner H-W. In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 1997;5:251–260
  14. Maj J. Behavioral effects of antidepressant drugs given repeatedly on the dopaminergic system. In:  Gessa GL,  Serra G editor. Dopamine and Mental Depression. Oxford: Pergamon Press; 1990;p. 139–146
  15. McTavish SV, Mannie ZN, Cowen PJ. Tyrosine depletion does not cause depressive relapse in antidepressant-treated patients. Psychopharmacology. 2004;175:124–126
  16. Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology. 1999;14:162–174
  17. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, et al. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of symptoms. Arch. Gen. Psychiatry. 1996;53:117–128
  18. Moresco RM, Colombo C, Fazio F, Bonfanti A, Lucignani G, Messa C, et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18]FESP on drug naïve depressed patients: a PET study. Neuroimage. 2000;12:452–465
  19. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology. 1992;109:433–438
  20. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In:  Zohar J,  Belmaker RH editor. Treating resistant depression. New York: PMA; 1987;p. 131–146
  21. Papp M, Wieronska J. Antidepressant-like activity of amisulpride in two animal models of depression. J. Psychopharmacol. 2000;14:46–52
  22. Papp M, Klimek V, Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology. 1994;115:441–446
  23. Ruther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, et al. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry. 1999;32:127–135
  24. Salomon RM, Miller HL, Delgado PL, Charney D. The use of tryptophan depletion to evaluate serotonin function in depression and other neuropsychiatric disorders. Int. Clin. Psychopharmacol. 1993;8(Suppl. 2):41–46
  25. Serra G, Forgione A, D'Aquila PS, Collu M, Fratta W, Gessa G. Blockade of DA autoreceptors: possible mechanism of antidepressant action of L-sulpiride. In:  Gessa G,  Serra G editor. Dopamine and mental depression. Oxford: Pergamon; 1990;p. 185–191
  26. Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. 1997;27:1247–1256
  27. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind comparative study. J. Affect. Disord. 1998;48:47–56
  28. Tiihonen J, Kuoppamaki M, Nagre K, Bergmen JM, Eronen E, Syvalahti E, et al. Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology. 1996;126:277–280
  29. Verbeeck WJC, Bert M, Pailer J, Jersky B. The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression. Eur. Neuropsychopharmacol. 2001;11:215–220
  30. Willner P. Sensitization to the actions of antidepressant drugs. In:  Emmett-Oglesby MV,  Goudie AJ editor. Psychoactive drugs: tolerance and sensitization. Clifton, NJ: Humana; 1989;p. 407–459
  31. Willner P. Validity, reliability and utility of the chronic mild stress (CMS) model of depression: a ten-year review and evaluation. Psychopharmacology. 1997;134:319–329
  32. Willner P. The mesolimbic dopamine system as a substrate for (rapid?) antidepressant action. Int. Clin. Psychopharmacol. 1997;12(Suppl. 3):S7–S14
  33. Willner P. Dopamine and depression. In:  Di Chiara G editors. Handbook of experimental pharmacology: dopamine in the CNS. Berlin: Springer; 2002;p. 387–416
  34. Willner P, Papp M. Animal models to detect antidepressants: are new strategies necessary to detect new agents?. In:  Skolnick P editors. Antidepressants: new pharmacological strategies. Totowa, NJ: Humana; 1997;p. 213–234
  35. Wong DF, Wagner HN, Pearlson G, Dannals RF, Links JM, Ravert HT, et al. Dopamine receptor binding of C-11-3-N-methyl-spiperone in the caudate of schizophrenic and bipolar disorder: a preliminary report. Psychopharmacol. Bull. 1985;21:595–598

PII: S0165-0327(04)00446-X

doi: 10.1016/j.jad.2004.12.010

Journal of Affective Disorders
Volume 86, Issue 1 , Pages 37-45 , May 2005

Article Tools

* Image Usage & Resolution